Szarkóma: vizsgálatok itt: Chile

3 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

• 3. fázisTaking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Santiago, Talca

  Életkor

  18 év and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00
• 2. fázisTaking people
  KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  Where

  Santiago

  Életkor

  18 év and over

  People

  140 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07252739 · EU 2025-521939-36-00
• 1/2. fázisTaking people
  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  Where

  Concepción, Santiago, Valparaíso

  Életkor

  6 hónap to 25 év

  People

  90 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06395103 · EU 2023-507178-41-00